| CASE REPORT |
|
| Year : 2020 | Volume
: 14
| Issue : 2 | Page : 200-202 |
|
|
Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
Soma Agrawal1, Mohit Chowdhry1, Prashant Karna1, Ankit Agrawal2
1 Department of Transfusion Medicine and Transplant Immunology, Indraprastha Apollo Hospital, New Delhi, India
2 Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, Saint Peter's University Hospital, New Brunswick, New Jersey, USA
Correspondence Address:
Dr. Soma Agrawal
Department of Transfusion Medicine and Transplant Immunology, Indraprastha Apollo Hospital, New Delhi - 110 076
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ajts.AJTS_19_19
|
|
|
CD38 is a disulfide-linked molecule present on red blood cells (RBCs) and daratumumab; an anti-CD38 monoclonal antibody is a novel agent for treating multiple myeloma patients. It also binds to the RBC along with the plasma cells in concern, creating a menace in the immunohematology workups and requires the use of dithiothreitol-treated cells to rule out its interference. Appropriate and timely communication with the clinicians about the patient history goes a long way in solving complex looking immunohematology workups. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
